Emcure Pharmaceuticals Ltd., a prominent player in the Indian pharmaceutical industry, is headquartered in Pune, India. Founded in 1981, the company has established a strong presence in various operational regions, including Asia, Africa, and the Americas. Emcure focuses on the development, manufacturing, and marketing of a diverse range of pharmaceutical products, including formulations, active pharmaceutical ingredients (APIs), and biosimilars. With a commitment to quality and innovation, Emcure has achieved significant milestones, such as receiving multiple international certifications and expanding its product portfolio to over 300 brands. The company is particularly noted for its expertise in oncology, cardiology, and anti-infectives, setting it apart in a competitive market. Emcure's dedication to research and development has solidified its position as a trusted name in healthcare, contributing to improved patient outcomes globally.
How does Emcure's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Emcure's score of 14 is lower than 92% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Emcure Pharmaceuticals, headquartered in India, currently does not report any specific carbon emissions data, as there are no available figures for emissions in kg CO2e. Additionally, the company has not established any documented reduction targets or commitments under frameworks such as the Science Based Targets initiative (SBTi). Without specific emissions data or reduction initiatives, it is unclear how Emcure is addressing its carbon footprint or contributing to climate action within the pharmaceutical industry. The absence of reported emissions and targets suggests a potential area for improvement in transparency and commitment to sustainability practices.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Emcure has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
